Nutshell Therapeutics wins FDA IND clearance for NTS231 NRF2 degrader
AI Summary- Nutshell Therapeutics received FDA IND clearance for its NTS231 NRF2 degrader.
- NTS231 is China’s first NRF2 degrader and the second globally entering clinical development.
- Nutshell completed IND approval within 24 months of target nomination, the company said.